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Rapid interrogation of the physical and chemical
characteristics of salbutamol sulphate aerosol
from a pressurised metered-dose inhaler (pMDI)†
H.-J. Tong,‡a C. Fitzgerald,a P. J. Gallimore,a M. Kalberer,a M. K. Kuimova,b
P. C. Seville,c A. D. Ward*d and F. D. Pope*e
Individual micron-sized solid particles from a Salamols pharmaceutical
inhaler are stably captured in air using an optical trap for the first time.
Raman spectroscopy of the levitated particles allows online interrogation
of composition and deliquescent phase change within a high humidity
environment that mimics the particle’s travel from inhaler to lung.
We investigate the physical and chemical evolution of the drug
salbutamol sulphate (SS) from a Salamols (manufacturer IVAX)
pressurised metered-dose inhaler (pMDI) which contains a suspen-
sion of crystalline SS in 1,1,1,2-tetrafluoroethane (HFA-134a) pro-
pellant and minute amounts of ethanol. Upon actuation, SS is
aerosolised generating micron sized particles. We compare the pMDI
generated SS particles to bulk crystalline sample of SS and nebulised
aqueous droplets of SS. This comparison permits the phase of the
pMDI generated SS to be determined. The bulk crystalline sample and
the nebulized aqueous solution of SS are used as reference systems.
An optical trap was used to probe the true aerosol phase of
both the pMDI generated SS particles and the nebulised SS
droplets. Optical trapping allowed for the stable levitation of the
aerosol particles within a purpose built environmental chamber
which mimicked the fast changing humidity encountered by
pMDI-generated aerosol. Optical trapping achieves particle
levitation by balancing the gravitational force, and the viscous
drag created by air flow, by an optical force;1 it allows aerosols
to be studied in a contact free manner and hence without the
artefacts that contact with a surface can induce.
Drugs are primarily delivered to the lung for the treatment of
conditions local to the airway; for example anti-asthmatic drugs
(e.g. salbutamol sulphate and beclometasone dipropionate).2
However, drug delivery to the lung is associated with a number
of diﬃculties, including the relative inaccessibility of the lungs,
necessitating the use of complex drug delivery devices to target
the drug to the appropriate area of the airways.
The pMDI is presently the device of choice, accounting for around
70% of inhaler sales in the UK3 and is the most frequently used
device for asthma and chronic obstructive pulmonary disease
(COPD).4 These devices contain the particles of the drug suspended
(or occasionally dissolved) in a pressurised gas, typically a hydrofluoro-
alkane propellant, along with relatively few other excipients (princi-
pally cosolvents such as ethanol or surfactants such as oleic acid).
Actuating the device releases a metered volume of the suspension
through an orifice contained within the pMDI housing;5 the released
pressurised suspension undergoes rapid flash evaporation and phase
expansion and forms inhalable solid aerosol particles.
The human respiratory tract eﬃciently filters atmospheric
aerosols through the microphysics of impaction, sedimentation
and diﬀusion. The size dependence of these competing processes
results in particles of diﬀerent sizes depositing in diﬀerent
regions of the respiratory tract.6 Particles in the size range
2–5 mm are optimal for delivering drugs into the central regions
of the lung and hence pMDI are formulated with micronized
drug particles in this size range.
If the inhaled particles are hygroscopic then their water content
and hence size and aerodynamic properties are dependent upon
the environmental relative humidity (RH) and the trajectory of the
aerosol particles though this environment. The RH environment of
a particle exiting the pMDI has three distinct regions: (1) completely
dry at the initial point of injection as the aerosol is released from
the canister, (2) at ambient RH as the patient inhales both the
aerosol and the ambient atmosphere, and finally (3) high RH as
the drug particles enters into the wet walled respiratory tract.
The change in RH from phase (2) to (3) is not monotonic. As the
particle travels deeper into the respiratory system it encounters
increasingly higher humidities:B40% in the mouth,B60% in
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the pharynx, to finally approaching near water saturation
B99.5% in the deep airways.6 The timescale of inhalation,
and particle impaction, is B10 s. Patients using pMDIs are
advised to actuate the device whilst simultaneously inhaling
slowly and steadily for 4 s, followed by a breath-hold of 10 s to
promote deposition by gravitational sedimentation.7
Hygroscopic particles moving from a region of low ambient
humidity into one of high humidity would be expected to increase
in size due to water uptake. A change in particle size will influence
the site of particle deposition in the lung following inhalation.8
A particle predicted to deposit in the central regions of the lungmay,
if substantial growth is experienced, deposit higher in the respiratory
tract than expected, potentially resulting in reduced therapeutic
eﬃcacy and increased incidence of side eﬀects (e.g. oral candidiasis
following deposition of corticosteroids in the oropharynx). To
mitigate these negative implications, the hygroscopic properties of
respirable drug formulations need to be understood. In particular
the kinetics of deliquescence and particle growth need to be
measured over the timescale (B10 s) of the journey of the aerosol
from pMDI to lung. The kinetics could be significantly influenced
by the morphology, size and/or phase of the particle and thus
investigating them for the real pMDI-generated, contact-free particle
is essential to obtain realistic results. Previous studies have investi-
gated the hygroscopicity of aqueous formulations of respirable drugs
generated by nebulizer e.g. Haddrell et al. 2014.9 To the best of our
knowledge this is the first in situ study of pMDI generated particles
which represent the dominant commercial methodology for trans-
porting aerosols into the lungs.
The optical trap used in this study utilized a new design of
counter-propagating dual beam (CPDB) configuration which we
recently reported.10,11 The trap is optimized to trap solid micron
sized particles over long timescales. This optical trapping configu-
ration can readily capture non-spherical aerosol particles. The
counter-propagating trapping beams are generated from the output
of a Nd:Yag laser operating at 1064 nm (Ventus, Laser Quantum).
Typical laser powers used are 14 mW through the top and 10mW
through the bottom objective lenses (see Fig. 1). To achieve stable
trapping the focal separation between the top and bottom beams was
adjusted toB10 mm which allowed for stable levitation of the same
particle for long time periods (41 hour). Most experiments were
carried out over shorter, medically relevant timescales.
The pMDI inhaler is discharged under ambient laboratory
relative humidity (ca. 30%) and is directed into a small bespoke
environment chamber, using a 20 cm length of Teflon tubing
(6 mm internal diameter). Inside the environmental chamber
the relative humidity can be varied, and very high subsaturated
relative humidities (498%) can be obtained.
The experiments were performed at ambient laboratory tempera-
ture ca. 20 1C. Within the chamber the humidity and temperature
were measured using a probe (Sensirion SHT75) positioned within
B1 cm of the trapping position. High humidity conditions were
achieved using a water reservoir within the chamber. Lower humid-
ity conditions were generated by flowing dry nitrogen, generated
from liquid nitrogen boil-oﬀ, through the chamber using a flow
controller (Bronkhorst MV-301) with flow rates up to 200 sccm.
The time taken from particle release from pMDI to levitation
within the optical trap was on the order of seconds and hence
the chamber could closely replicate the residence time and the
RH trajectory of the particle in the lung.
Aqueous droplets of SS were generated from a 0.05 M solution
of SS (99% Alfa Aesar) in MilliQ water using an ultrasonic nebulizer
(Schill Mobil Aerosonic 3060). No attempt was made to replicate
the minute amounts of ethanol cosolvents present in the Salamols
pMDI formulation and the role of ethanol is assumed to be
negligible. The solution generated droplets were trapped within
the CPDB trap in the diameter size range 1–2 mm.
To obtain spectroscopic information regarding particle composi-
tion a 514.5 nm Ar-ion laser (Innova 308C, Coherent) was focused
onto the trapped particle through the lower objective with a power of
2mWat focus (see Fig. 1). This light source was used to generate both
Raman and fluorescent (if present) signal which provide composi-
tional information about the probed particle. Both the Raman and
fluorescent signal were directed to a spectrograph (Spectrapro 2500i,
1200 groove blazed at 500 nm) and imaged onto a CCD camera
(Princeton Instruments, Spec10). Each particle was only subjected to
the 514.5 nm laser for 30 s to minimize heating and fluorescent
bleaching eﬀects.12 This necessitates using fresh particles for every
measurement. In addition to spectroscopic interrogation the trapped
particles/droplets were imaged using brightfieldmicroscopy. Formore
detail on the optical strategy, see Rkiouak et al. 2014.10
Optical trapping of particles can lead to particle heating through
absorption of the laser radiation incident on the particle. The extent
of the heating depends upon the characteristics of the laser beam
(wavelength, power and beam profile) and the absorption character-
istics of the particle and surrounding medium.13,14 The increase in
particle temperature above the ambient conditions, caused by
absorption of the 514.5 and 1064 nm laser beams, is estimated
using an approach similar to Knox and Reid.15
At the typically used laser powers it is estimated that a pure
salbutamol sulphate particle of 2 mmdiameter would be 1.4 1Cwarmer
than the ambient conditions (see ESI†).
The optical trap configuration was extremely successful at
trapping solid pMDI generated particles over a range of particle
Fig. 1 Schematic cartoon of the experimental setup showing the trapping
and Raman laser paths and high humidity particle trap.
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sizes and shapes. The trapped particle size ranged from ca. 1–3 mm.
The measured asymmetry factor corresponded to particle shapes
ranging from spheres to rods (Fig. 2). The trap only ever contains
one particle at a time as observed through bright field microscopy.
Panel A in Fig. 2 provides representative brightfield microscopy
images of levitated pMDI particles with asymmetry increasing from
left to right. The brightfield images of SS nebulised droplets and SS
particles at high humidity both display more intense illumination
at the centre of the particle, typical for the illumination of micro-
spheres. Dry particles do not display this characteristic.
Panel B compares the particle size histograms of particles
caught within the optical trap and the total particle output from
the pMDI. The C panels compare the sphericity of optically trapped
particles, under high and low humidity conditions, with the total
pMDI output obtained by imaging a coverslip at ambient RH.
The size and sphericity of the total output from the pMDI is
measured by releasing several puﬀs of the pMDI into the environ-
mental chamber, without the optical trap active, and letting the
particles settle onto the coverslip through gravitational sedimentation.
The sizes and shapes of the resulting particle ensemble are then
imaged using the brightfieldmicroscope. Particle size and shape were
analysed using the image analysis software ImageJ (release 1.48) with
particle size defined by the longest axis of the particle, and the particle
sphericity defined by the reciprocal of the aspect ratio. The measured
particle size was calibrated using a graticule placed on themicroscope.
In Fig. 2 panel B, the optical trap captures particles that are
representative of the full output size range of the pMDI. The modal
size for both the levitated particles and full inhaler output isB2 mm.
However, the optical trap’s particle size distribution is narrower. It
does not stably capture the smallest (o1 mm) or the larger particles
(43.5 mm) that are observed in the full output of the pMDI.
The observed trapped particle sizes and shapes were consistent with
the measured aerosol output of pMDI from previous studies.16
Under low RH conditions, the particles caught in the optical trap
tend to be more spherical than the average particle exiting the pMDI
(Fig. 2C2 vs. Fig. 2C3). This is likely due to the optical trap requiring
some degree of symmetry in the particle shape for eﬃcient trapping.
The sphericity of the trapped particles increases significantly under
high humidity conditions, suggesting that water uptake by the
particles increases particle sphericity (Fig. 2C1). No increase in
average size was observed between low and high RH particles
because the trap is optimized to a certain size range (B1–3 mm).
The chemical and physical properties of the SS aerosol particle
were followed using optical imaging, Raman spectroscopy and
fluorescence spectroscopy. Raman spectra of optically trapped pMDI
generated particles weremeasured over a wide range of RH (10–98%).
The spectra of pMDI particles were compared to the spectra from
both bulk crystalline SSmaterial deposited on a coverslip and optically
trapped aqueous droplets of SS generated through nebulization
(Fig. 3). The Raman spectrum of the crystalline SS from this study
is similar to that previously recorded by Ali et al. but the spectral
resolution in this study is greater.17 The four largest intensity peaks at
780, 978, 1255 and 1615 rel. cm1 are assigned to n(C–C–O), n(COH),
d(CH) and hydrogen bonded C–OH, respectively.17 The spectra of SS
droplets generated from nebulization of aqueous SS contain a strong
fluorescence signal superimposed upon the SS Raman peaks which
are significantly broadened compared to the crystalline sample. The
Raman peak broadening in solution is likely due to the increase in
vibrational energy configurations of the SS once water molecules are
available for interaction via hydrogen bonding. Previous studies have
also observed the fluorescence of solution phase SS.18,19
The pMDI generated particles show two distinct spectra which
are dependent upon RH. At RH belowB92% the spectra are near-
identical to the bulk crystalline material, confirming that the
particles generated by the pMDI are largely crystalline in composi-
tion as they exit the pMDI. The particles caught in the chamber at
RH greater than B92% show similar spectra but with significant
peak broadening similar to the nebulised SS droplets. All four major
peaks (780, 978, 1255 and 1615 rel. cm1) and the 750 rel. cm1
peak show significant broadening at elevated RH, as shown in Fig. 3.
There is also significant growth in the peak at 1450 rel. cm1.
We attribute the step change in peak broadening atB92%RH to
a previously unreported SS deliquescent phase transition. We note
that amorphous SS particles have a distinct Raman spectrum20 and
therefore the transformation at ca. 92% RH is unlikely to be caused
by a crystalline to amorphous phase transition.
To further investigate the phase transition we looked at the peak
broadening inmore detail. In particular, we investigated the 750 and
780 rel. cm1 peaks. These peaks were chosen because they reside in
a spectrally simple region and can be successfully fitted with two
Lorentzian profiles with low associated error. The results of the
780 rel. cm1 peak fitting are shown in the right panel of Fig. 3.
There is a large and obvious change in the peak width of the
780 cm1 band after deliquescence. Before deliquescence the average
full width at half maximum (FWHM) is 6.5  0.7 rel. cm1 and
after deliquescence the width is 28.3  1.8 rel. cm1, where the
errors are 1s. The FWHM width of 750 cm1 peak also changes
significantly upon deliquescence with the pre-deliquescence
and post-deliquescence values equal to 6.0  0.9 rel. cm1
Fig. 2 Imaging, characterising and comparing levitated particle with total pMDI
output on coverslip. Panel A – example images of levitated SS particles with
sphericity decreasing from left to right (scale bar = 2 mm). Panel B – histograms
of particle diameter (major axis). Panel C – histograms of particle sphericity
caught in the optical trap under low (C1) and high (C2) RH conditions, and
output collected on cover slip (C3). The histograms are constructed from data
from 62 optically levitated particles and 534 particles on the coverslip.
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and 11.6  1.4 rel. cm1, respectively. The peak broadening
analysis determines the RH value at which the deliquescence
phase transition occurs: 91.9 2.7%. The error is dominated by
the RH probe accuracy as stated by the manufacturer.
Simple peak broadening analysis on the other three major peaks
(978, 1255, 1615 rel. cm1) give qualitatively very similar results with
a clear transition occurring at ca. 92% RH. Notably, the phase
transition is possibly only partial on the timescale of the experiment,
as evidenced by the lack of complete particle sphericity in all
particles (Fig. 2C1). However, the lack of sphericity could also be
largely explained by error in the particle size measurement.21
Interestingly, no fluorescence signal was observed from the
levitated particle at RH either above or below the deliquescence point.
However, fluorescence is highly sensitive to the presence and concen-
tration of solvents as well as pH.22 A polar solvent like water can lead
to lower energy fluorescence emission at longer wavelengths.22 Hence
we would expect the fluorescence properties of nebulized droplets to
be distinct from particles generated by a pMDI regardless of the RH
due to the higher water content of nebulized particles.
We provide a new methodology to study the physical and
chemical characteristics of SS aerosol directly as it exits from a
commercially available pMDI without changing its physical–
chemical properties. Furthermore we interrogate the changes in
aerosol characteristics that occur once the aerosol enters into a
purpose built high humidity environment chamber which is used
as a proxy for the human respiratory tract. This study focused on
the output from a Salamols inhaler, but the technique presented
should be universal for all pMDI devices. SS particles are observed
to deliquesce at 91.9  2.7% RH as evidenced by three separate
pieces of information: significant peak broadening in the Raman
spectrum, increased particle sphericity and the emergence of a
central bright spot within the brightfield images which is indicative
of droplets. Thus, following release from the Salamols pMDI into
the high RH environment of the respiratory tract, crystalline SS
takes up water via deliquescence, resulting in an increase in particle
sphericity. This change in particle size, phase and morphology will
affect the aerodynamic properties of the aerosol, and should be
considered when modelling the aerosolization performance of
inhalation products. In addition, exposure to high RH results in
the change of crystalline to liquid phase which will almost certainly
promote drug dissolution, and hence the kinetics of drug uptake,
following the deposition of the droplet onto the epithelial lining of
the respiratory tract. The reported experiments were performed at a
temperature lower than the human body and at RH slightly less
than saturation. Future work will focus onmore realistic proxies for
the respiratory tract.
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Fig. 3 Left panel: oﬀset Raman spectra of SS. Black line – Raman signal of
crystalline SS (Alfa Aesar) deposited on the cover slip. Blue, brown, purple
and green line – Raman signal from a single SS particle injected from the
pMDI (Salamols) into the environmental chamber and optically trapped at
12, 92, 94 and 98% RH, respectively. Red line – Raman and fluorescence
signal from single SS droplet generated by nebulization of aqueous SS
solution. Right panel: width (FWHM of fitted Lorentzian function) of the
peak at 780 cm1, which is highlighted by the blue band in the left panel.
The yellow band indicates the SS deliquescence point.
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